Thane: KIMS Doctors Perform High-Risk Nephron-Sparing Surgery On Complex Renal Tumor

In a highly challenging case, a 55-year-old woman suffering from a complex renal tumor located dangerously close to the ...
Cancer Therapy Advisor

In RCC, Local Recurrence After Nephron-Sparing Treatment Increases Mortality Risk

After nephron-sparing treatment for RCC, patients with local recurrence had a higher mortality risk than patients without recurrence.
Targeted Oncology

Perioperative Disitamab Vedotin/Tislelizumab Shows Promise in High-Risk UTUC

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
AOL

Years after warning from FDA, Nephron sees ‘egregious’ violations in inspection

Despite multiple warnings from the Food and Drug Administration about its manufacturing processes, Nephron Pharmaceuticals, one of the largest employers in Lexington, has continued to face federal ...